Biogen Says Data Show Spinraza Improved Motor Function in Later-Onset Spinal Muscular Atrophy

By Michael Dabaie

Biogen Inc. (BIIB) said data show individuals with later-onset spinal muscular atrophy treated with Spinraza regained motor function that had been previously lost.

Biogen said Tuesday that data from a study of the safety and tolerability of Spinraza in individuals with later-onset spinal muscular atrophy were published in the peer-reviewed journal Neurology.

Patients, aged five up to 19, treated with Spinraza over three years demonstrated clinically significant improvements in motor function and stabilization of disease activity, the company said. One individual gained the ability to walk independently, which hasn't been previously observed in untreated individuals with SMA Type 2, Biogen said.

Data also demonstrated long-term durability and safety of treatment in individuals with later-onset SMA, including SMA Type 3, the company said.

As of March 31, more than 7,500 patients have been treated with Spinraza in more than 40 countries.

Write to Michael Dabaie at [e-mail]

(END) Dow Jones Newswires

April 30, 2019 12:37 ET (16:37 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.